CATALOGO DEI PRODOTTI DELLA RICERCA

MAURELLI, MARTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.298
EU - Europa 3.082
AS - Asia 2.378
SA - Sud America 307
Continente sconosciuto - Info sul continente non disponibili 125
AF - Africa 121
OC - Oceania 18
Totale 10.329
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.103
RU - Federazione Russa 1.276
SG - Singapore 898
IT - Italia 551
CN - Cina 457
GB - Regno Unito 265
BR - Brasile 240
HK - Hong Kong 239
DE - Germania 228
VN - Vietnam 190
FR - Francia 158
IE - Irlanda 154
FI - Finlandia 116
SE - Svezia 116
IN - India 108
CA - Canada 91
JP - Giappone 79
BD - Bangladesh 77
KR - Corea 77
ES - Italia 49
ID - Indonesia 47
NL - Olanda 42
IQ - Iraq 38
SA - Arabia Saudita 33
TR - Turchia 29
TG - Togo 25
AR - Argentina 23
MX - Messico 22
UA - Ucraina 22
BE - Belgio 21
IL - Israele 20
AT - Austria 19
BJ - Benin 19
EG - Egitto 17
NG - Nigeria 16
CR - Costa Rica 15
GT - Guatemala 13
SV - El Salvador 13
ZA - Sudafrica 13
AU - Australia 12
PL - Polonia 12
PH - Filippine 11
PK - Pakistan 10
EC - Ecuador 9
SC - Seychelles 9
VE - Venezuela 9
CH - Svizzera 8
CW - ???statistics.table.value.countryCode.CW??? 8
IR - Iran 8
JM - Giamaica 8
MY - Malesia 8
NI - Nicaragua 8
CO - Colombia 7
HU - Ungheria 7
CL - Cile 6
TW - Taiwan 6
AL - Albania 5
GR - Grecia 5
HN - Honduras 5
KE - Kenya 5
MA - Marocco 5
PR - Porto Rico 5
UY - Uruguay 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
BG - Bulgaria 4
DK - Danimarca 4
NZ - Nuova Zelanda 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
BO - Bolivia 3
CZ - Repubblica Ceca 3
JO - Giordania 3
KZ - Kazakistan 3
LB - Libano 3
LK - Sri Lanka 3
LT - Lituania 3
OM - Oman 3
PE - Perù 3
TN - Tunisia 3
AG - Antigua e Barbuda 2
AM - Armenia 2
BB - Barbados 2
BN - Brunei Darussalam 2
DM - Dominica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GE - Georgia 2
NP - Nepal 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AO - Angola 1
BS - Bahamas 1
BW - Botswana 1
CG - Congo 1
CI - Costa d'Avorio 1
CY - Cipro 1
Totale 10.194
Salva come PNG Salva come JPEG
Città #
Dallas 648
Ashburn 577
San Jose 491
Singapore 454
Moscow 440
Chandler 244
Hong Kong 231
Council Bluffs 186
Dublin 139
Verona 118
Munich 112
Beijing 107
New York 98
The Dalles 89
Southend 87
Los Angeles 77
Ho Chi Minh City 73
Helsinki 70
Milan 67
Santa Clara 52
London 48
Jacksonville 45
Rome 38
Hanoi 37
Lawrence 34
Princeton 34
Paris 33
Buffalo 32
Lappeenranta 31
Jakarta 30
Redondo Beach 30
São Paulo 29
Wilmington 28
Washington 26
Amsterdam 25
Lomé 25
Chennai 24
Bologna 23
Frankfurt am Main 23
Manchester 22
Riyadh 22
Tokyo 22
Chicago 21
Phoenix 21
Houston 20
Madrid 20
Sindelfingen 20
Woodbridge 20
Atlanta 19
Cotonou 19
Mumbai 19
Seattle 19
McKinney 18
Najaf 18
Jinan 17
Montreal 17
Monza 17
North Bergen 16
Orem 16
Abuja 15
Shanghai 15
Toronto 15
Boston 14
Haiphong 14
Nuremberg 14
Annandale 12
Barcelona 12
Denver 12
Naples 12
River Grove 12
San Salvador 12
Bethnal Green 11
Ghaziabad 11
Nanjing 11
Warsaw 11
Ann Arbor 10
Brasília 10
Brooklyn 10
Brussels 10
Guangzhou 10
Guatemala City 10
Liverpool 10
San José 10
Vancouver 9
Ankara 8
Cairo 8
Dongguan 8
Islington 8
Istanbul 8
Managua 8
Miami 8
Redwood City 8
Tianjin 8
Willemstad 8
Baghdad 7
Bari 7
Chieri 7
City of London 7
Fairfield 7
Giza 7
Totale 5.752
Salva come PNG Salva come JPEG
Nome #
Clinical features and treatments of transient acantholytic dermatosis (Grover’s disease): a systematic review 404
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 369
A systematic review of treatments for pityriasis lichenoides 358
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16-week multicentre retrospective study 279
Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study 271
Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature 225
Gender perspective in the management of psoriasis 207
Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective Study 193
BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. 186
Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products 184
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series 176
Psoriasin (S100A7) is increased in serum of patients with moderate to severe psoriasis 174
A case of genital primary syphilis with superimposed impetigo 168
Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid 167
Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature 165
Neutrophilic figurate erythema: report of a new case in an adult and comparison between adult and paediatric cases 154
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis 148
Advanced Glycation End Products and Psoriasis 148
A man with a widespread bullous eruption 145
Annular Erythema: New and Revisited Variants 144
Incidence and ten-year follow-up of primary cutaneous lymphomas: a single-centre cohort study 142
Uncommon Non‑Infectious Annular Dermatoses 141
Amicrobial Pustulosis of the Folds: Report of Three New Cases 141
Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis 139
Adrenergic urticaria successfully treated with omalizumab 138
Safety and Efectiveness of Upadacitinib in Patients with Moderate‐to‐Severe Atopic Dermatitis Who Smoke: a 2‐Year Real‐Life Multicenter Study 136
Idiopathic lichenoid and granulomatous dermatitis 136
Clinical profile and co-infections of urethritis in males 133
Price variability of TNF-α inhibitor biosimilars among European countries 132
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis 131
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease 131
Atopic Dermatitis in the Elderly Population 130
Interferon-beta injection site reactions in patients with multiple sclerosis. 127
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients 125
Biological agents targeting interleukin-13 for atopic dermatitis 125
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis 122
Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series 119
Managing the Patient with Psoriasis and Metabolic Comorbidities 118
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes 117
IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review 117
Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination 113
FARMACOECONOMIA APPLICATA ALLE MALATTIE INFIAMMATORIE CRONICHE CUTANEE (PSORIASI E DERMATITE ATOPICA) 112
Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients 112
Milia-like calcinosis cutis in Down syndrome: a new case with a review of the literature 111
Lichen planopilaris coexisting with plaque psoriasis effectively treated with brodalumab 106
Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo 105
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260‐Week Real‐World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) 104
Long‑Term Effectiveness and Safety of Ixekizumab for the Treatment of moderate‑to‑Severe Plaque Psoriasis: A Five‑Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) 101
Severe cutaneous aluminum reaction to quadrivalent human papillomavirus vaccine treated with cyclosporin 99
The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases 97
Eosinophilic annular erythema successfully treated with cyclosporine 96
Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines 95
Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis: A 5-year multicentre retrospective study—IL PSO (Italian landscape psoriasis) 93
Palisaded neutrophilic granulomatous dermatitis and its associations with autoimmune diseases 92
Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle 89
Efcacy and safety of JAK inhibitors in patients aged >60 years with moderate‐to‐severe atopic dermatitis: a 52‐week multicenter, real‐life study—IL AD (Italian Landscape Atopic Dermatitis) 88
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 88
Pruritus as a Distinctive Feature of Type 2 Inflammation 86
Visual Vignette 85
Targeting IL-4 for the Treatment of Atopic Dermatitis 84
Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience 80
Tailored biological treatment for patients with moderate-to-severe psoriasis 80
null 80
The Combination of Dupilumab with Other Monoclonal Antibodies 79
Is risankizumab as needed administration a good option for patients with plaque psoriasis? 78
Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment 78
Overview of Atopic Dermatitis in Different Ethnic Groups 77
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS) 76
Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis 72
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study 70
Lymphoplasmacytic plaque effectively treated with imiquimod 67
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis 66
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis 60
Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study 58
Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations 50
Letter: Optimizing Dupilumab Dosing in Atopic Dermatitis: Real-World Evidence 36
Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis 35
Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and prior inefficacy of T helper 2 biologics: a propensity score-matched study 34
Klinische Merkmale und Behandlungen der transitorischen akantholytischen Dermatose (Morbus Grover): ein systematischer Review 30
Refractory Lichen Amyloidosis Successfully Treated with Upadacitinib: A Case Report and Literature Review 29
Biosimilars for chronic plaque psoriasis: a 2026 update 28
Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis) 27
The Girl with a Pearl Earring: A dermatological puzzle 26
Real‑World Efficacy of IL‑23 Inhibitors in Psoriasis Affecting High‑Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis) 25
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate‐to‐Severe Atopic Dermatitis: A Multicentre Real‐World Study: IL‐AD (Italian Landscape Atopic Dermatitis) 24
Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study 23
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis) 18
Real-world comparison of IL-23 inhibitors in moderate-to-severe plaque psoriasis: a focus on super responders—IL PSO (Italian landscape Psoriasis) 18
Clinical Characteristics of Patients Presenting with Moderate-to-Severe Atopic Dermatitis and Concomitant Inflammatory Bowel Diseases: a Multicenter Retrospective Study 17
Real‐World Long‐Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study 17
Dermatologic manifestations in an adult with Williams syndrome 16
Efficacy and Safety of Delgocitinib and Its Impact on Patient’s Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study 16
Real-life effectiveness and safety of lebrikizumab in older patients with atopic dermatitis: a multicentre study 7
Patient‑Level Cumulative Clinical Benefit of Brodalumab Over 52 Weeks: A Multicentre Real‑World Study‑IL PSO (Italian Landscape Psoriasis) 6
Sex Differences in Epidemiology, Mechanisms, and Management of Atopic Dermatitis 5
Totale 10.329
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.668
article - articoli 37.753
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 360
patent - brevetti 0
selected - selezionate 0
volume - volumi 555
Totale 77.336
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022171 0 0 0 0 31 6 6 23 4 14 30 57
2022/2023738 38 68 63 134 58 187 16 34 90 13 25 12
2023/2024647 16 30 56 51 52 126 115 42 8 39 71 41
2024/20251.894 119 63 98 291 80 115 168 111 244 136 143 326
2025/20264.927 293 169 674 610 1.141 273 428 293 340 392 137 177
2026/20271.539 276 210 201 711 141 0 0 0 0 0 0 0
Totale 10.329